TOP > クイック検索 > 外国特許検索 > PREDICTIVE FACTOR AND TESTING METHOD FOR THE ONSET OF ARTERIOSCLEROTIC DISEASES

PREDICTIVE FACTOR AND TESTING METHOD FOR THE ONSET OF ARTERIOSCLEROTIC DISEASES NEW

外国特許コード F170009162
整理番号 (S2016-0444-N0)
掲載日 2017年9月6日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP005836
国際公開番号 WO 2017142055
国際出願日 平成29年2月17日(2017.2.17)
国際公開日 平成29年8月24日(2017.8.24)
優先権データ
  • 特願2016-027867 (2016.2.17) JP
発明の名称 (英語) PREDICTIVE FACTOR AND TESTING METHOD FOR THE ONSET OF ARTERIOSCLEROTIC DISEASES NEW
発明の概要(英語) The present invention provides a diagnostic marker and onset risk evaluation method for arteriosclerotic diseases. More specifically, the present invention provides a method for evaluating the onset risk of an arteriosclerotic disease, wherein the C5a protein in a blood sample is adopted as a diagnostic marker for the arteriosclerotic disease, and the method includes a step for measuring, in vitro , the amount of the C5a protein in a blood sample collected from a subject, and a step for evaluating the onset risk of arteriosclerosis or vascular inflammation in the subject by using the amount of the C5a protein as an indicator. This method is useful for evaluating the onset risk of an arteriosclerotic disease at an extremely early stage.
特許請求の範囲(英語) [claim1]
1. Being the method of appraising the emergence risk of the artery hardenable disease,
The process which measures the quantity of the C5a protein in the blood sample which is obtained from the suffering inspection person with in vitro, and
The process which appraises the emergence risk of the artery hardenable disease in the suffering inspection person with the quantity of the C5a protein as an index
Implication,
The aforementioned suffering inspection person, density in the blood which statistics has not increased significantly by comparison with reference level 1 or possesses plural factors, 1 where it is selected or they are plural factors from the group where said factor consists of TNF-.alpha., IL-1.alpha., IL-1.beta., IL-7 and IL-11,
When measurable quantity of the quantity of the aforementioned C5a protein being large statistics significantly by comparison with reference level, when emergence risk of the artery hardenable disease in the aforementioned subject is high it decides, method.
[claim2]
2. The aforementioned suffering inspection person is 75 years old or more, method of claim 1 statement.
[claim3]
3. The plaque not yet formation or is undeveloped in the aforementioned suffering inspection person, claim method of 1 or 2 statements.
[claim4]
4. The artery hardenable disease, the ateromu artery muscardine and the blockade characteristic artery muscardine, the myocardial blockage and the brain blockage, stroke, the heart attack, the cerebral thrombosis, the apoplexy, or is the kidney incomplete, either of the claim 1-3 in one section method of statement.
[claim5]
5. The polypeptide which possesses the arrangement to which the aforementioned C5a protein is shown in SEQ ID NO 1 or it is that mutant or fragment, either of the claim 1-4 in one section method of statement.
[claim6]
6. The aforementioned measurement it is done the C5a protein making use of the connection possible substance uniquely, either of the claim 1-5 in one section method of statement.
[claim7]
7. -description above connection possible substance antibody be be, claim section 6 to statement method.
[claim8]
8. The aforementioned blood sample the serum, the blood plasma, or is all blood, either of the claim 1-7 in one section method of statement.
[claim9]
9. The anti- C5a antibody, the fragment, and/or those chemical decoration derivatives are included, the kit for appraisal of emergence risk of artery hardenable disease.
[claim10]
10. Either of the claim 1-8 it is something in order to use for the method of statement in one section, in claim 9 the kit of statement.
[claim11]
11. The aforementioned antibody, the fragmentary or chemical decoration derivative is connected to the solid phase carrier, in claim 9 or 10 the kit of statement.
[claim12]
12. The aforementioned solid phase carrier the strip for inspection, is the plastic tube, the micro plate or the glass beads, in claim 11 the kit of statement.
[claim13]
13. Obstructs with the remedy of the artery hardenable disease or being the composition in order to use for prevention, as the active ingredient, the substance which the connection of the C5a protein and the C5a receptor is included, the composition.
[claim14]
14. The substance which obstructs the connection with the aforementioned C5a protein and the C5a receptor is the C5a receptor antagonist, in claim 13 the composition of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKYO MEDICAL AND DENTAL UNIVERSITY
  • 発明者(英語)
  • YOSHIDA MASAYUKI
  • OSAKA MIZUKO
国際特許分類(IPC)
指定国 (WO2017142055)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close